Kalaris Therapeutics, Inc.

KLRS

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001754068

None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $121.7M
Warnings	dilution, thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	6 of 13
Graded from	filings received through Mar 17, 2026 245 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026
Last close	$1.46 2026-11-16; market equity $34.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor ("VEGF") drug, specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a "decoy receptor" (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.1						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(7.9%)	(6.7%)	49.1	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 41.8					
Altman Z double-prime	0.97	0.31	33.8	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	(31.98x)	(3.61x)	79.5	74	2025-12-31
Current ratio	12.23x	2.68x	12.2	781	2025-12-31
Growth and financing, sleeve percentile 90.4					
Revenue growth, three-year compound	not computable	9.6%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	(24.0%)	3.2%	88.2	663	2025-12-31
Net share issuance, one year	354.6%	1.6%	92.6	624	2026-03-10

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 354.6%
Thin data	6 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(42.5%)	(1.7%)	20
Distance from 52-week high	(86.7%)	(31.5%)	6
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(111.0%)	0.5%	6
Book value to price	1.36	0.28	91
Sales to price	not computable	0.36	
Composite equity issuance, five years	212.9%	13.2%	92
Relative strength against the sector, log excess return	(0.73)	(0.19)	20
Twelve-month failure probability, CHS model	0.29%	0.06%	79

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$47.4M
Operating cash flow, four quarters	-$40.2M
Months of runway	14.1
Days since last periodic filing	7 (10-Q received Nov 10, 2026)
Median daily dollar volume, 63 sessions	$167,090

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$43.4M	2025-12-31	2026-03-17	10-K	26-110659
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.4M	2025-12-31	2026-03-17	10-K	26-110659
3	assets	us-gaap:Assets	$121.7M	2025-12-31	2026-03-17	10-K	26-110659
4	assets	us-gaap:Assets	$6.2M	2024-12-31	2026-03-17	10-K	26-110659
5	current assets	us-gaap:AssetsCurrent	$118.8M	2025-12-31	2026-03-17	10-K	26-110659
6	current liabilities	us-gaap:LiabilitiesCurrent	$9.7M	2025-12-31	2026-03-17	10-K	26-110659
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$160.0M	2025-12-31	2026-03-17	10-K	26-110659
8	operating income	us-gaap:OperatingIncomeLoss	-$46.2M	2025-12-31	2026-03-17	10-K	26-110659
9	book equity	us-gaap:StockholdersEquity	$78.8M	2025-12-31	2026-03-17	10-K	26-110659
10	liabilities	us-gaap:Liabilities	$42.9M	2025-12-31	2026-03-17	10-K	26-110659
11	interest expense	us-gaap:InterestExpense	$1.4M	2025-12-31	2026-03-17	10-K	26-110659
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$200,000	2025-12-31	2026-03-17	10-K	26-110659
13	depreciation amortization	us-gaap:Depreciation	$13,000	2025-12-31	2026-03-17	10-K	26-110659
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$43.4M	2025-12-31	2026-03-17	10-K	26-110659
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-17	10-K	26-110659
16	current assets	us-gaap:AssetsCurrent	$2.6M	2024-12-31	2026-03-17	10-K	26-110659
17	current liabilities	us-gaap:LiabilitiesCurrent	$24.7M	2024-12-31	2026-03-17	10-K	26-110659
18	assets	us-gaap:Assets	$190.8M	2023-12-31	2025-03-07	10-K	25-035143
19	assets	us-gaap:Assets	$277.1M	2022-12-31	2024-03-15	10-K	24-031879
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,928,303	2026-03-10	2026-03-17	10-K	26-110659
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,043,357	2025-02-28	2025-03-07	10-K	25-035143

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.